皓 赵

- Built the new China Precision Medicine team from the ground up; lead 23 reports across central marketing (2) and a 20+ field force, and serve as a member of the Oncology Business Unit (OBU) leadership team. - Drove double-digit OBU business growth by maximizing the potential of biomarker-related indications and managing the full patient journey from diagnosis to treatment. - Set the strategy-level approach to patient identification and an execution-level, scientifically creative model to differentiate from competitors. - Authored MSD China's long-term Precision Medicine strategy, including pipeline and new-technology implementation; involved in the business plan and P&L for each precision-medicine-related indication.

- Led the global launch of gastrointestinal (GI) biomarkers and ran the first GI University workshop, aligning regions on diagnostic strategy. - Drove global ADC–digital pathology strategy development and launched the supporting market research. - Shaped China-focused precision-medicine and early-detection strategies (lung and liver) to identify new business.

- Built and led a diagnostics-focused go-to-market strategy for Lynparza, raising clinician awareness of companion-diagnostic testing. - Enabled in-hospital NGS testing capability across 100+ hospitals plus external access, expanding BRCA testing reach to 90%+ of target customers; secured testing quality through national QC programs. Facilitated the BRCA and the HRD testing rate with 30-40% improvement. - Led a team of 12 (3 managers, 9 specialists) with under 10% annual turnover and zero compliance incidents.

- Oversaw a cross-functional team of one Pharma Development Manager, three Technical Support Sales, five Regional Sales, and two Bioinformatics Specialists. Under this leadership, tumor-related reagent sales increased by 25% by 2019. - Integrated key resources from global teams, local diagnostics (Dx) companies, pharmaceuticals, oncologists, and pathologists to introduce oncology molecular testing solutions—generating revenue through routine clinical testing and pharma companion diagnostics development projects. - Expanded the company’s oncology portfolio with innovative applications, including Tarceva T790M digital PCR testing, Vemurafenib MET-14 skipping testing, and BeiGene TCR preclinical research, effectively opening new business channels.

- Developed and implemented robust business strategies that drove expansion from biomarker development and translational medicine into companion diagnostics, resulting in the establishment of four Oncomine and NGS OEM partnerships and collaborations with over ten NGS diagnostic companies based on Ion Torrent technology. - Recognized for leadership excellence, receiving the “Best Project Leader” award in 2017 and the “Best Marketing” award in 2018.

– Positioned the target customers for this start-up company and developed market strategies for molecular diagnosis of tumors, including products for breast cancer recurrence risk assessment and identification of primary tumor site. – Developed distribution channels and managed the direct sales team, developed clinical and pathological KOLs nationwide, promoted the medical value of molecular markers through market activities and patient education, thus achieved sustained monthly growth in the first year.

- Led and executed the full launch process for tumor gene mutation diagnostic reagents (cobas EGFR/KRAS/BRAF) and the cobas z 480 qPCR platform in China. Through strategic collaboration with Roche Pharmaceuticals, these new oncology diagnostics were introduced to core hospitals, establishing the first cohort of domestic molecular pathology KOLs and enhancing clinicians’ understanding of companion diagnostics.

- Introduced a fully automated urine analyzer and urine sediment analyzer; directed cross-departmental development of urine analysis software, thereby strengthening core competitiveness and differentiating the products from competing analyzers.

- Served as the primary liaison for regular business communications and reporting with Israeli manufacturers. - Provided comprehensive product solutions and technical support to scientific research clients, encompassing PCR instruments, high-pressure sterilizers, and other routine laboratory equipment.